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Abstract
Receptor tyrosine kinases (RTK) and their ligands control critical biologic processes, such as cell proliferation, migra-
tion, and differentiation. Aberrant expression of these receptor kinases in tumor cells alters multiple downstream
signaling cascades that ultimately drive the malignant phenotype by enhancing tumor cell proliferation, invasion, me-
tastasis, and angiogenesis. As observed in human glioblastoma (hGBM) and other cancers, this dysregulation of RTK
networks correlates with poor patient survival. Epidermal growth factor receptor (EGFR) and c-Met, two well-known
receptor kinases, are coexpressed inmultiple cancers including hGBM, corroborating that their downstream signaling
pathways enhance a malignant phenotype. The integration of c-Met and EGFR signaling in cancer cells indicates that
treatment regimens designed to target both receptor pathways simultaneously could prove effective, though resis-
tance to tyrosine kinase inhibitors continues to be a substantial obstacle. In the present study, we analyzed the anti-
tumor efficacy of EGFR inhibitors erlotinib and gefitinib and c-Met inhibitor PHA-665752, along with their respective
small hairpin RNAs (shRNAs) alone or in combination with human umbilical cord blood stem cells (hUCBSCs), in
glioma cell lines and in animal xenograft models. We also measured the effect of dual inhibition of EGFR/c-Met path-
ways on invasion and wound healing. Combination treatments of hUCBSC with tyrosine kinase inhibitors significantly
inhibited invasion andwound healing in U251 and 5310 cell lines, thereby indicating the role of hUCBSC in inhibition of
RTK-driven cell behavior. Further, the EGFR and c-Met localization in glioma cells and hGBM clinical specimens indi-
cated that a possible cross talk exists between EGFR and c-Met signaling pathway.
Translational Oncology (2012) 5, 379–392
Introduction
The aggressive nature and dismal prognosis of glioblastoma multi-
forme (GBM) highlights the need for novel therapeutic options. Re-
cent advances in the molecular characterization of GBM have exposed
new potential mechanisms for targeted therapeutic agents. Studies on
patients with human GBM (hGBM) detailed molecular alterations in
the epidermal growth factor receptor (EGFR), indicating its crucial
role in the development and progression of glioblastoma [1,2]. Be-
cause EGFR and other receptor tyrosine kinases (RTKs) and their
ligands control critically important biologic processes, such as cell
proliferation, migration, and differentiation, aberrant expression of
these receptor kinases by the tumor cells or by nonmalignant tumor-
infiltrating cells alters multiple downstream signaling cascades [3].
These changes may ultimately drive the malignant phenotype by en-
hancing tumor cell proliferation, invasion, metastasis, and angiogenesis
[4–6]. In addition to EGFR, c-Met expression is also correlated with
tumor grade in different cancers, where it is known to have a similarly
Address all correspondence to: Andrew J. Tsung, MD, Illinois Neurological Institute,
530 NE Glen Oak Avenue, Peoria, IL 61637. E-mail: Andrew.J.Tsung@INI.org
1This research is supported by a grant from the Illinois Neurological Institute (A.J.T.).
The funders had no role in study design, data collection and analysis, decision to pub-
lish, or preparation of the manuscript. The authors declare no conflict of interest exists
with this manuscript.
2This article refers to supplementary materials, which are designated by Figures W1
and W2 and are available online at www.transonc.com.
Received 9 July 2012; Revised 12 July 2012; Accepted 13 July 2012
DOI 10.1593/tlo.12235
www.transonc.com
Trans la t iona l Onco logy Volume 5 Number 5 October 2012 pp. 379–392 379
Copyright © 2012 Neoplasia Press, Inc.
1944-7124/12
Open access under CC BY-NC-ND license.
prominent role in cellular proliferation, motility, invasion, angiogenesis,
and survival [7–10]. Overexpression of c-Met presages a poor prognosis
and correlates with malignant grade in glial neoplasms [11]. EGFR and
c-Met are often coexpressed in several malignancies, such as astrocytoma,
lung, head and neck, breast, and colon cancers, and the convergent
downstream signaling pathways of both kinases enhance a malignant
phenotype [12–17]. Glioblastoma cells treated with hepatocyte growth
factor (HGF) demonstrated increased tumorigenicity, whereas block-
ade of c-Met in vivo inhibited tumor formation, thereby implying its
pivotal role in tumor formation [18].
Despite their intricacy, it is thought that cell surface receptors EGFR
and c-Met elicit similar signal transduction pathways; therefore, their
cross talk could affect the strength and duration of shared subsequent
signaling pathways [19]. Furthermore, immunoprecipitation experi-
ments conducted on SUM229 cells demonstrated physical and func-
tional interactions between EGFR and c-Met [20]. The relatively
high frequency of crossover between these tumor-promoting signaling
pathways makes it worthwhile to study the clinical efficacy of their
respective inhibitors. The tyrosine kinase inhibitors (TKIs) gefitinib,
erlotinib, and PHA-665752 targeted to EGFR/c-Met have shown
promising results in patients with glioblastoma [21–25]. Unfortu-
nately, only a subpopulation of these patients responds clinically
to the inhibitors, even though most patients with hGBM express
EGFR/c-Met in their tumors [26]. Considering the apparent dominant
role of EGFR in GBMs, targeted therapies that inhibit the functions of
EGFR or c-Met may also have strong antitumor activity. However,
since oncogenic tyrosine kinases orchestrate highly complex signaling
pathways, the key drug-induced changes conferring sensitivity could
be difficult to identify. Although agents against specific targets have
shownmodest activity in several clinical trials, there is a need to develop
more effective strategies involving combined EGFR/c-Met–targeted
therapy owing to the synergistic antitumor effects of combining EGFR
and c-Met pathway inhibition.
Due to their tumor targeting properties, human umbilical cord
blood stem cells (hUCBSCs) present a new therapeutic strategy. In
our previous reports, we have shown that hUCBSCs have the capacity
to induce apoptosis, regulate cell cycle progression, and inhibit in vivo
tumor growth [27,33]. In the present study, we examined the anti-
tumor efficacy of hUCBSC alone or in combination with well-known
EGFR/c-Met inhibitors, such as shRNA to EGFR, erlotinib, gefitinib,
and PHA-665752, in U251 and 5310 cells as well as in cells obtained
from hGBM patient specimens. To further delineate the antitumor
effects of combined targeting of EGFR and c-Met using hUCBSCs
and inhibitors, we examined the effect of dual inhibition of both
pathways on invasion and wound healing. We further determined
the efficacy of combined treatment in decreasing the expression of
important downstream signaling molecules intrinsic to both EGFR
and HGF/c-Met pathways.
Materials and Methods
Antibodies and Reagents
We used the following antibodies: rabbit anti-EGFR, goat anti-
pEGFR, mouse anti-EGFR, rabbit anti–c-Met, rabbit anti–p-c-Met,
rabbit anti-Stat3, mouse anti–β-catenin, mouse anti-AKT, rabbit anti–
p-AKT, goat anti–phosphoinositide 3-kinase (PI3K), goat anti–p-PI3K,
mouse anti–glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(1:200 dilution), and c-Met small-interfering RNA (siRNA) (sc-29397)
were purchased from Santa Cruz Biotechnology Inc (Santa Cruz, CA).
The c-Met inhibitor, PHA-665752, was obtained from Sigma-Aldrich
(St Louis, MO). Erlotinib hydrochloride and gefitinib hydrochloride
were obtained from Santa Cruz Biotechnology Inc. AG1478 was
obtained from Calbiochem (San Diego, CA).
hUCBSC Culture
hUCBSCs were collected from healthy donors with informed con-
sent according to the protocol approved by the University of Illinois
College of Medicine at Peoria Institutional Review Board. hUCBSC
were isolated using Ficoll-Paque (GE Healthcare, Piscataway, NJ) den-
sity gradient centrifugation. The isolated cells were plated in 100-mm
plates in Dulbecco modified Eagle’s medium (DMEM) knockout
medium (Invitrogen, Carlsbad, CA) supplemented with 10% FBS,
10% knockout serum (Hyclone, Logan, UT), and 1% penicillin/
streptomycin. When the adherent cells reached 20% to 30% con-
fluence, they were supplemented with MesenCult medium (Stem
Cell Technologies, Vancouver, Canada) containing human mesen-
chymal stem cell stimulatory supplements (Stem Cell Technologies)
and 1% penicillin/streptomycin (Invitrogen). For coculture experi-
ments, hUCBSC and glioma cells were cultured at a ratio of 1:1. Co-
cultures of hUCBSC and U251 were grown in DMEM; cocultures
of hUCBSC and 5310 were grown in RPMI-1640 medium.
Glioma Cell Culture
U251 cells obtained from the National Cancer Institute (Frederick,
MD) were grown in DMEM supplemented with 10% FBS (Hyclone)
and 1% penicillin/streptomycin (Invitrogen). Xenograft cell line 5310
(a kind gift from Dr D. James of the University of California, San
Francisco) was grown in RPMI-1640 medium supplemented with
10% FBS and 1% penicillin/streptomycin at 37°C. To visualize
and identify two different populations of cells in the hUCBSC co-
culture studies with glioma cell lines U251 and 5310, we used stan-
dard flow cytometry technique as described previously [27].
Human Glioma Xenograft Cell Line
JKR-14 xenograft cells were isolated from a biopsy specimen from
a 54-year-old male patient with glioblastoma. Xenografts were main-
tained in the flanks of athymic homozygous NU/J mice (Strain No.
2019 from Jackson Laboratory, Bar Harbor, ME), and early passages
in RPMI-1640 medium were used to minimize genetic drift.
Construction of shRNA-Expressing Plasmid and
Transfection of shEGFR
The plasmid vector, pSilencer 4.1-CMV (Ambion, Austin, TX), was
used in the construction of the shRNA-expressing vector, and the
human EGFR sequence AAGACTGCTAAGGCATAGGAA was the
shRNA target sequence. Inverted repeat sequences were synthesized for
EGFR. The inverted repeats were laterally symmetrical, making them
self-complimentary with a 9-bp mismatch in the loop region that
would aid in the loop formation of the shRNA. Oligonucleotides were
heated in a boiling water bath in 6× SSC for 5 minutes and self-
annealed by slow cooling to room temperature. The annealed oligo-
nucleotides were ligated to pSilencer vector at BamHI and HindIII
sites. Cells at 60% to 70% confluence in 100-mm tissue culture plates
were transfected with 7 μg of shRNA-expressing plasmid constructs
[shRNA specific for EGFR (shEGFR)] using FuGene HD following
the manufacturer’s instructions (Roche, Indianapolis, IN).
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Single and Combination Treatments
U251 and 5310 cells were treated with either 5 μM erlotinib or
gefitinib hydrochloride for 9 hours, 10 μMAG1478 for 1 hour, 0.5 μM
PHA-665752 for 9 hours, or with 10 ng of recombinant EGF (rEGF;
Millipore, Billerica, MA) for 1 hour. In all of the combination treat-
ments, cells were pretreated with shEGFR, rEGF, or PHA-665752
for their respective time points and then were cocultured with hUCBSC
(1:1 ratio) for 72 hours.
Western Blot Analysis
Cells from various treatment groups were collected and lysed in
RIPA buffer [50 mmol/ml Tris-HCl (pH 8.0), 150 mmol/ml NaCl,
1% IGEPAL (octylphenoxypolyethoxyethanol), 0.5% sodium deoxy-
cholate, and 0.1% sodium dodecyl sulfate (SDS)] containing 1 mM
sodium orthovanadate, 0.5 mM phenylmethylsulfonyl fluoride (PMSF),
10 μg/ml aprotinin, and 10 μg/ml leupeptin, and the lysates were
then resolved using SDS–polyacrylamide gel electrophoresis (PAGE).
After transfer onto nitrocellulose membranes, blots were blocked with
5% nonfat dry milk in phosphate-buffered saline (PBS) and 0.1%
Tween-20. Blots were incubatedwith respective primary antibodies, fol-
lowed by incubation with a horse radish peroxidase (HRP)-conjugated
secondary antibody. Immunoreactive bands were visualized using
chemiluminescence enhanced chemilumescent (ECL) Western blot
detection reagents onHyperfilmMP autoradiography film (Amersham,
Piscataway, NJ). GAPDH antibody was used to verify equal loading of
proteins in all lanes.
Wound Healing Assay
For wound healing migration assay, a straight scratch was made
manually in subconfluent cell monolayers using a sterile 200-μl pipette
tip in individual wells, and cells were allowed to migrate into the cell-
free area. This point was considered the “0 hour,” and the width of the
wound was immediately photographed under the light microscope.
The cells were observed for ∼12 to 20 hours depending on the cell
line [28].
Matrigel Invasion Assay
Matrigel invasion assay was used to assess cell invasive potential
as described previously [29]. Cell culture medium supplemented
with 10% FBS was added to the lower chamber to act as a chemo-
attractant. U251 and 5310 control cells, alone or in coculture with
hUCBSC, were seeded at a density of 2 × 105 cells/well onto the upper
inserts and then incubated at 37°C. After 24 hours, the noninvasive
cells were removed from the upper surface of the separating membrane
by gentle scrubbing with a cotton swab, and the invading cells were
fixed in 100% methanol and stained with 2-hydroxyethyl methacrylate
(Hema)–3. Similar experimental procedures were used when we
investigated the inhibitory effects of EGFR shRNA–, PHA-665752–,
and rEGF-mediated invasion.
Immunoprecipitation Analysis
Protein lysates were prepared from 3 to 5 mm3 pieces of frozen intra-
cranial tumors. Approximately 200 to 400 μg of protein cell lysates
were incubated at 4°C with 50 μl of Protein G/A beads (Miltenyi
Biotec, Auburn, CA), followed by sequential additions of 10 μl (2 μg)
of EGFR and c-Met antibodies with end-to-end rotation overnight.
The immunoprecipitates were then loaded onto “μ” columns (Miltenyi
Biotec) and rinsed with lysis buffer according to the manufacturer’s
instructions. The columns were washed twice with 200 μl of lysis
buffer. Preheated (95°C) 1× SDS gel loading buffer was loaded onto
the column matrix using a fresh pipette tip and incubated at room tem-
perature for 5 minutes. After discharging the supernatant, 50 μl of
1× SDS gel loading buffer was added to the immunoprecipitates, and
the supernatants were then collected and loaded into 8% to 12% SDS-
PAGE followed by electrophoretic transfer to nitrocellulose mem-
branes for further analysis.
Immunocytochemistry
Cells were grown in two-well chamber slides, washed with PBS,
fixed, permeabilized with ice-cold methanol, and blocked with 10%
goat serum for 1 hour. Cells were incubated with primary antibodies
for either 2 hours at room temperature or overnight at 4°C, washed
with PBS, and incubated with fluorescent-labeled, species-specific
secondary antibodies (Alexa Fluor) for 1 hour at room temperature.
Before mounting, the slides were washed with PBS, stained with
4′,6-diamidino-2-phenylindole (DAPI) for nuclear staining, and analyzed
under a microscope (Olympus BX61 Fluoview, Minneapolis, MN).
Immunohistochemical Staining
For detection of EGFR and c-Met, 5-μm sections of formalin-fixed,
paraffin-embedded tissues of U251 and 5310 controls or hUCBSC-
treated or hGBM tissues were deparaffinized and subjected to antigen
retrieval for 10 minutes at 90°C in 0.1M sodium citrate buffer (pH 6.0).
Next, sections were washed in PBS and blocked in 10% goat serum for
30 minutes. A 1:100 dilution of mouse anti-EGFR and rabbit anti–
c-Met antibodies in 10% goat serum was added to sections, which
were incubated overnight at 4°C. After washing in PBS, sections were
incubated with HRP-conjugated goat anti-mouse and goat anti-rabbit
immunoglobulin G (IgG), respectively. These sections were washed in
PBS and developed with the DAB substrate (Sigma-Aldrich) to produce
color. The specificity of EGFR and c-Met staining was confirmed by a
lack of staining without primary antibody or an isotype-matched
irrelevant antibody. After counterstaining with hematoxylin, sections
were mounted, cleared, coverslipped, and examined using a confocal
microscope. For immunofluorescence, sections were treated with pri-
mary antibodies overnight at 4°C and then treated with appropriate
Alexa Fluor secondary antibodies at room temperature for 1 hour.
Negative controls were maintained either without primary antibody
or using respective IgG. All immunostained sections, which were
stained with fluorescent antibodies, were counterstained with DAPI.
The sections were blind reviewed by a neuropathologist.
Cell Cycle Analysis Using Flow Cytometry
Progression of glioblastoma through different cell cycle phases in
varying concentrations of erlotinib and gefitinib was monitored by
flow cytometric analysis. DNA content was analyzed by staining with
propidium iodide and carried out with an FACS (FACSCalibur flow
cytometer; Becton Dickinson, San Jose, CA). The percentage of cells
within G1, S, G2, and M phases was determined using CellQuest soft-
ware. Approximately 10,000 events were counted for each analysis,
and three to four independent experiments performed in triplicate
were conducted for each group (n = 3).
Intracranial Administration of Glioma Cells and
hUCBSC in Nude Mice
The Institutional Animal Care and Use Committee of the Univer-
sity of Illinois College of Medicine at Peoria approved all surgical
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interventions and postoperative animal care. Glioma cells were injected
intracerebrally into the right side of the brains of nude mice with 10-μl
aliquots of U251 and 5310 (1 × 106) cells under isofluorane anesthesia
with the aid of a stereotactic frame. hUCBSCs were injected left of the
sagittal suture and bregma of mouse brain after a week of tumor im-
plantation. The ratio of the hUCBSC to cancer cells was maintained at
1:4. Three weeks after tumor inoculation, six mice from each group
were sacrificed by intracardiac perfusion, first with PBS and then with
4% formaldehyde in PBS. The removed brains were stored in 4% para-
formaldehyde, processed, embedded in paraffin, and sectioned (5 μm
thick) using a microtome. Paraffin-embedded sections were stained
with hematoxylin and eosin to visualize tumor cells.
Statistical Analysis
Quantitative data from cell counts, FACS analysis, Western blot
analysis, and other assays were evaluated for statistical significance
using one-way analysis of variance (ANOVA). Data for each treatment
group were represented as means ± SEM and compared with other
groups for significance by one-way analysis of variance followed by
Bonferroni post hoc test (multiple comparison tests) using GraphPad
Prism version 3.02, a statistical software package. Results were consid-
ered statistically significant at P < .05.
Results
EGFR Knockdown Suppresses c-Met Signaling
To determine the effect of EGFR expression on c-Met and c-Met–
mediated cellular signaling networks, we transfected U251 and 5310
glioblastoma cells with shEGFR and performed Western blot analy-
sis. The Western blot results revealed that the total EGFR was re-
duced to 28% in U251 and to 38% in 5310 control cells, whereas
the phosphorylated EGFR (pEGFR) levels were reduced to 38% and
49% in U251 and 5310 cells, respectively.We also observed that c-Met
expression levels correlated with EGFR levels, with 34% and 38%
reductions in U251 and 5310 cells. Overexpression and activity of
Stat3 and β-catenin have been linked to the invasion and metastasis
of several cancers in humans [30,31] and their reliance on EGFR/c-Met
signaling [32]. Further, the relative expression levels of EGFR/c-Met
downstream signaling molecules such as Stat3 and β-catenin in
shEGFR-transfected samples were attenuated to 23% and 16% in
U251 cells and 21% and 19% in 5310 cells, respectively (Figure 1,
A and B). Furthermore, the immunocytochemical analysis of
shEGFR-transfected U251 and 5310 cells showed reduced expression
levels of c-Met, p-c-Met, Stat3, and β-catenin (Figure 1, E and F). To
confirm that the decreased expression of EGFR/c-Met signaling mole-
cules is because of the EGFR knockdown, we serum starved the two cell
lines for 3 hours and then substituted them with serum-starved medium
containing rEGF (10 ng/ml) for 1 hour with subsequent immunoblot
analysis. We observed that EGFR expression was enhanced by 25% in
U251 cells and by 27% in 5310 cells, whereas the pEGFR levels were
found to be increased by 69% and 71% in EGF-treated U251 and
5310 cells, respectively. Interestingly, the c-Met levels were increased
to 59% and 68% in U251 and 5310 cells, respectively, and showed
increase in the expression of downstream signaling molecules Stat3
and β-catenin (Figure 1, C and D). These results indicate that EGFR-
mediated downstream signaling represents an integrated signaling
cascade resulting from the coactivation of c-Met receptors.
EGFR Inhibitors Annihilate c-Met Signaling Molecules
To analyze the sensitivity of U251 and 5310 cells to EGFR target-
specific drugs, we studied the tolerance of two different EGFR kinase
inhibitors, erlotinib and gefitinib. Initially, the GBM cells were treated
with increasing concentrations (1, 5, and 10 μM) of erlotinib and
gefitinib and were compared with untreated cells at different time
points (3, 6, 9, and 24 hours). Both erlotinib and gefitinib showed
time-dependent and dose-dependent inhibition of EGFR with maxi-
mal inhibition at 5 μM for 9 hours of treatment. Significant cell death
was observed when the cells were incubated more than 24 hours. Fol-
lowing erlotinib treatment, pEGFR levels were observed to be reduced
even at the lower concentrations, although no statistically significant
effects on the cell proliferation were observed (Figure W1, A–C ).
Furthermore, at 5 μM concentration of erlotinib, the expression levels
of c-Met were reduced along with its phosphorylated form, p-c-Met.
Cosuppression of key ancillary molecules like Stat3 and β-catenin
was also confirmed by Western blot analysis (Figure 2, A and B). Stud-
ies with 5 μM concentration of gefitinib demonstrated similar, but not
identical, results. The expression levels of pEGFR, c-Met, p-c-Met, and
β-catenin displayed a decrement compared to what was observed with
erlotinib in U251 cells, whereas β-catenin expression was comparable in
both erlotinib and gefitinib treatments (Figure 2, A and B). To examine
if other EGFR inhibitors can also inhibit c-Met downstream signal-
ing molecules, we treated the U251 and 5310 GBM cells with 10 μM
AG1478. The levels of EGFR (total and phosphorylated forms) along
with c-Met, Stat3, and β-catenin proteins were decreased in U251
and 5310 glioblastoma cell lines as determined byWestern blot analysis
(Figure 2, C and D). Similarly, to demonstrate that EGFR activation
was a direct consequence of c-Met receptor, we treated U251 and 5310
cells with PHA-665752, a specific c-Met kinase inhibitor. Western blot
analysis revealed a suppression of EGFR phosphorylation levels accom-
panied by a concomitant decrease in the phosphorylation status of c-Met
and reduced Stat3 and β-catenin expression levels (Figure 2, E and F).
hUCBSC Treatment Suppresses
EGFR/c-Met–Mediated Signaling
Oncogenic tyrosine receptor kinases sit at the top of multiple sig-
naling pathways that are constitutively activated upon increased phos-
phorylation of these RTKs. Coculture treatment of U251 and 5310
cells with hUCBSC for 72 hours has demonstrated reduced expres-
sion of total and phosphorylated forms of EGFR. Apart from EGFR,
c-Met, Stat3, and β-catenin levels were also reduced by more than
50% in both GBM cell lines (Figure 3, A and B). Though the protein
expression levels varied in both the cell lines tested, the end effect
was similar and comparable to the immunoblot analysis of mouse
xenograft samples (Figure 3, C and D). To further validate the speci-
ficity of the treatments, we cocultured shEGFR-treated cells with
hUCBSC. The expression levels of EGFR/c-Met signaling molecules
were significantly reduced when compared to the small molecule in-
hibitor treatments alone or hUCBSC-alone treatments (Figure 3, E
and F ). In separate experiments, glioma cells were subjected to serum
starvation for 3 hours and then treated with rEGF (100 ng/ml) for
1 hour. The cells that were given EGF treatment were cocultured with
hUCBSC in 1:1 ratio for 72 hours. Western blot analysis performed
on these lysates demonstrated that addition of rEGF increased the
EGFR/c-Met signaling molecules, and further, this increase was
suppressed noticeably with treatments (Figure 3, G and H ), thereby
indicating the hUCBSC potential role in down-regulation of EGF-
induced EGFR/c-Met signaling pathway in glioma cells.
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Combination of shEGFR and PHA-665752 with hUCBSC
Coculture Treatments Showed Enhanced Inhibition
of GBM Cell Invasion and Wound Healing
The overexpression of EGFR with other cell surface receptors like
c-Met has been reported independently to affect the efficacy and
offers resistance to targeted therapies [17]. On the basis of these find-
ings, we hypothesized that combined targeting of both EGFR and
c-Met pathways with hUCBSC treatment might increase antitumor
efficacy in U251 and 5310 cells. Further, we used the clinically rele-
vant c-Met kinase inhibitor PHA-665752 in combination with
shEGFR and hUCBSC coculture treatments to study the wound heal-
ing ability of U251 and 5310 cells. We have previously shown that
hUCBSC inhibits the wound closure in glioma cells [33]. In the pres-
ent study, we observed that wound healing was inhibited by 50%
and 57% with shEGFR, 80% and 71% with rEGF (10 ng/ml) +
hUCBSC, 57% and 61% with PHA-665752, 67% and 74% with
PHA-665752 + shEGFR, and 82% and 81% with PHA-665752 +
hUCBSC treatments in U251 and 5310 cells, respectively. Wound
Figure 1. EGFR knockdown by specific shRNA reduces c-Met expression. (A) Down-regulation of EGFR by an EGFR-specific shRNA
results in loss of c-Met phosphorylation in both U251 and 5310 cells when transfected for 72 hours. Corresponding whole-cell lysates
were immunoblotted with anti-Met, anti-Stat3, and β-catenin antibodies. GAPDH served as a loading control (SV, scrambled vector).
(B) Quantitation of A. (C) U251 and 5310 cells were serum starved for 3 hours and then treated with 10 ng/ml rEGF for 1 hour. Total
and phosphorylated EGFR, c-Met, Stat3, β-catenin, and β-actin levels were detected by Western blot analysis. The results shown are
representative of three independent experiments. (D) Quantitation of C. The results presented in this study are the representative
images of three independent experiments (n = 3) and are expressed as means ± SE; *P < .05; **P < .01. (E, F) Immunofluorescence
staining using anti-Met, p-c-Met, anti-Stat3, and β-catenin antibodies followed by an Alexa Fluor 594–tagged secondary antibody was
performed in shEGFR-transfected U251 and 5310 cells compared to the SV controls. Panels were photographed at 20×. Red indicates
the expression levels of the respective proteins, whereas DAPI is used to stain the nucleus. Scale bars, 200 μm.
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closure in untreated U251 and 5310 cells was measured between 16
and 24 hours, whereas in EGF-treated cells wound closure was ob-
served between 12 and 16 hours (Figure 4A). Statistically significant
differences in all the treatments compared to the control cells are dis-
played as a bar graph (Figure 4B). We next investigated the role of
EGFR and c-Met inhibitors on GBM cell invasion. We performed
the Matrigel invasion assay using U251 and 5310 glioma cells treated
with shEGFR, PHA-665752, and EGF alone or in combination with
hUCBSC. In both of the cell lines tested, the shEGFR and PHA-
665752 treatments significantly reduced the number of invaded cells
versus controls, and this reduction was further decreased in combina-
tion treatments (Figures 4C and W2A). Further to substantiate our
findings that combination treatments were more effective on glioma
cells, we treated U251 and 5310 cells with erlotinib, PHA-665752,
Figure 2. RTK inhibitors, erlotinib, gefitinib, AG1478, and PHA-665752, reduce EGFR/c-Met cross activation in U251 and 5310 glioblas-
toma cells. (A) U251 and 5310 cells were grown in serum-starved medium containing 5 μM erlotinib and gefitinib for 9 hours. Cell lysates
were evaluated for the expression levels of total and phosphorylated EGFR, c-Met, Stat3, and β-catenin. (B) Quantitative estimation of A.
(C) To study the effect of EGFR phosphorylation of c-Met expression, we treated U251 and 5310 cells with 10 μM AG1478 for 1 hour in
serum-starved medium. Expression levels of various molecules were subjected to Western blot analysis. (D) Quantitative estimation of
C. (E) The phosphorylation of EGFR, c-Met, Stat3, and β-catenin is substantially reduced by 0.5 μM PHA-665752 in U251 and 5310 cells.
Cells treated only with DMSO were treated as controls. Cells were lysed, and the indicated proteins were detected by immunoblot
analysis with indicated antibodies. (F) Bar graph quantification values of E. Values are the means ± SE of three independent experi-
ments; *P < .05; **P < .01. All the data represented in this panel are representative of two individual separate experiments. In all the
experiments, the Western blots were normalized using GAPDH.
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Figure 3. hUCBSC controls the expression levels of EGFR and c-Met. We performed immunoblot analysis to study the expression of
EGFR and its downstream signaling molecules in the (A) cell lysates (in vitro) and (C) tissue lysates of brains extracted from nude mice
(in vivo). Orthotopic intracranial tumors were established in nude mice by injecting glioma cells (U251 and 5310) and then treating with
hUCBSC. Equal amounts of proteins (40 μg) from untreated (control) and hUCBSC-treated cell lysates and tissue lysates were loaded
onto 8% to 14% gels and transferred onto nitrocellulose membranes, which were then probed with respective antibodies. GAPDH was
used a positive loading control. (B and D) The relative band intensities were measured by densitometry and normalized against the
respective GAPDH signals. (E) U251 and 5310 cells were transfected with shEGFR and then allowed to coculture with hUCBSC for
72 hours at a 1:1 ratio. (G) U251 and 5310 cells were treated with rEGF and then subjected to coculture. In both experiments, cell lysates
were analyzed for the expression levels of EGFR, pEGFR, c-Met, Stat3, and β-catenin in various treatment groups. (F and H) Quantifi-
cation of E and G. Values are the means ± SE of three independent experiments, each with three samples per experimental treatment;
*P < .05; **P < .01.
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Figure 4. Combined treatment with shEGFR and PHA-665752 maximally inhibits wound healing and invasion comparable to hUCBSC
coculture treatments. (A) Wounds were generated in confluent U251 and 5310 cells in six-well plates using a sterile 200-μl pipette tip.
Cells were then exposed to different treatments: shEGFR, 10 ng/ml EGF, 10 ng/ml EGF-treated cells cocultured with hUCBSC, 0.5 μM
PHA-665752, 0.5 μM PHA-665752–treated cells cocultured with hUCBSC, and 0.5 μM PHA-665752 cells transfected with hUCBSC.
Wound closure was assessed under a microscope at 10× magnification. (B) Cell migration distance was measured for each wound
and compared with baseline measurements and was plotted as a bar graph. Values are the means ± SE of three independent experi-
ments; *P < .05; **P < .01; ***P < .001. (C) Serum-starved cells using the above conditions were plated in Biocoat Matrigel Transwell
chambers. Cells were allowed to invade for 24 hours, fixed, stained, and counted at 10× magnification. Values are the means ± SE of
three independent experiments; *P < .05; **P < .01. (D) U251 and 5310 cells were grown in serum-starved medium containing 5 μM
erlotinib, 0.5 μM PHA-665752, and 5 μM erlotinib + 0.5 μM PHA-665752 for 9 hours. Cell lysates were evaluated for the expression
levels of total and phosphorylated forms of both EGFR and c-Met. (E) Both U251 and 5310 cells were transfected for c-Met–specific
shRNA for 72 hours. Corresponding whole-cell lysates were immunoblotted for total and phosphorylated forms of EGFR and c-Met,
Stat3, and β-catenin antibodies with respective antibodies. GAPDH served as a loading control.
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and PHA-665752 in combination with erlotinib. We found that
erlotinib treatment reduces pEGFR expression effectively when com-
pared to the total and phosphorylated forms of c-Met. PHA-665752,
the c-Met inhibitor, effectively decreases the expression of c-Met and
phosphorylated forms, compared to the EGFR expression. Interest-
ingly, U251 and 5310 cells treated with EGFR and c-Met inhibitors
demonstrated additive reduction in the EGFR and c-Met expres-
sion (Figure 4D). In another experiment, we attempted to examine
the c-Met silencing using siRNA specific to c-Met. Western blot anal-
ysis revealed that c-Met siRNA showed a small reduction in the expres-
sion of pEGFR levels, whereas Stat3 and β-catenin levels were reduced
to maximum, pointing to the fact that c-Met operate through the
downstream signaling molecules, Stat3 and β-catenin (Figure 4E ).
Together, these data suggest that both EGFR and c-Met pathways
play an important role in the glioma cell migration and invasion; reg-
ulating these pathways by means of hUCBSC treatment may lead to a
greater reduction in invasive and migratory capabilities, which is of
utmost importance to prevent the infiltration of healthy nontumor
brain tissue by glioblastoma cells.
hUCBSC Inhibits Physical Association of EGFR and
c-Met in Glioblastoma Cells
The expression of EGFR and c-Met in U251 and 5310 cells was
examined by immunocytochemical and immunohistochemical anal-
yses. We observed that the EGFR and c-Met overexpressed in U251
and 5310 cells and were entirely colocalized; EGFR immunoreactivity
was superimposed with that of c-Met in U251 and 5310 glioma cells.
In contrast, in hUCBSC cocultured cells, EGFR and c-Met expres-
sions were reduced to a minimum and revealed minimal colocaliza-
tion (Figure 5A). To corroborate in vitro immunocytochemical
Figure 5. hUCBSC coculture reduces EGFR/c-Met localization. (A) We carried out immunocytochemistry of U251 and 5310 cells either
alone or in coculture with hUCBSC to study the colocalization of EGFR/c-Met. EGFR is conjugated with Alexa Fluor 594 (red), and c-Met is
conjugated with Alexa Fluor 488 (green). Scale bar, 100 μm. (B) Similarly, dual immunohistochemical staining for colocalization in U251
and 5310 controls and hUCBSC-treated mouse xenografts was conducted with anti-EGFR and anti–c-Met antibodies followed by the
secondary antibodies conjugated with fluorophores for red and green fluorescence, respectively. Representative merged images show
the cells expressing EGFR/c-Met. Scale bar, 100 μm. Each experiment was performed in triplicate with each sample (n = 3).
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results, we processed U251 and 5310 tissue sections using the same
experimental protocols. Figure 5B shows the fluorescence micro-
graphs of immunostained U251 and 5310 control tissue sections,
with EGFR strongly overlapping with c-Met, demonstrating their
strong association in glioma cells.
EGFR Coprecipitates with c-Met in Mouse Xenografts and
hGBM Patient Tissue Specimens
EGFR may be phosphorylated by itself or by a different receptor
family member through heterodimerization. Alternatively, constitutive
phosphorylation of c-Met by addition of exogenous EGF in A431 cells
suggested the heterodimeric association between the two EGFR and
c-Met receptors [8]. To elucidate this cross talk, we immunopre-
cipitated tissue lysates from U251 and 5310 controls along with the
hUCBSC treatments or tissue lysates obtained from hGBM patient
specimens (hGBM10–hGBM14) using anti-EGFR antibodies and
immunoblotted against anti-EGFR and c-Met antibodies. We
observed coimmunoprecipitation of these proteins in control U251
and 5310 and hGBM lysates, whereas hUCBSC-treated U251 and
5310 cells showed reduced interaction of EGFR and c-Met proteins
(Figure 6, A and B). The reverse pull-down assay using a c-Met anti-
body also confirmed their association (Figure 6, C and D). EGFR and
c-Met did not coprecipitate in normal human brain samples. The glioma
control tissue lysates and hGBM tissue lysates demonstrated high levels
of EGFR and c-Met expression. Further, in a separate experiment,
Western blot analysis of these patient-derived samples demonstrated
increased expression levels of total and phosphorylated forms of EGFR
and c-Met, along with their downstream signaling molecules, Stat3
and β-catenin (Figure W2B). Earlier, Lee et al. [34] demonstrated that
tumors derived from patients with hGBMmirror genotypic and pheno-
typic characteristics of standard glioma cell lines. In the present study,
we observed that EGFR and c-Met were coexpressed in five hGBM
patient–derived specimens. Furthermore, the high EGFR and c-Met
expression levels were also confirmed in the patient specimens when
Figure 6. EGFR and c-Met interact and colocalize in hGBM patient specimens. Eight hundred micrograms of total soluble protein from
(A) U251 and (B) 5310 control and hUCBSC-treated tissue lysates or from (C) hGBM patient specimens was immunoprecipitated with
EGFR, and the samples were immunoblotted against c-Met. The same blots were stripped and reprobed with anti-EGFR antibody. In a
reverse experiment, above tissue lysates were immunoprecipitated with c-Met and were immunoblotted against EGFR. The same blots
were stripped and reprobed with anti–c-Met antibody. (E) Representative immunohistochemical staining of EGFR and c-Met in human
GBM patient specimens and normal brain. Scale bars, 200 μm. Strong positivity of EGFR and c-Met was detected in all the five specimens
(hGBM10, hGBM11, hGBM12, hGBM13, and hGBM14) tested. Negative staining was seen in normal human brain samples. (F) Repre-
sentative micrographs of colocalization studies of EGFRwith c-Met in the hGBM14 sample. Red indicates EGFR, whereas green indicates
c-Met. Scale bars, 200 μm.
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compared to normal brain specimens using immunohistochemistry
(Figure 6E). Following this confirmation, we tested their association
in hGBM14 specimen. Figure 6F demonstrates that EGFR is associ-
ated with c-Met, thus implying the existence of EGFR/c-Met mech-
anism in the hGBM subjects.
hUCBSC Treatment Regulates EGFR/c-Met Expression
in Primary Glioma JKR-14 Cells; EGFR and c-Met
Signal through Common PI3K/Akt Axis
To prove that our laboratory coculture studies on established GBM
lines U251 and 5310 conform to preclinical standards, we isolated
cells (JKR-14) from a 54-year-old male patient with GBM. Using
immunocytochemical analysis, untreated JKR-14 cells demonstrated
increased expression of both EGFR and c-MET, whereas the hUCBSC
coculture treatment reduced the expression of both EGFR and c-Met
and further suppressed their association (Figure 7A). Moreover, the
decreased expression of total and phosphorylated forms of EGFR and
c-Met signaling molecules in JKR-14 as examined by Western blot
analysis substantiates our immunocytochemical results (Figure 7B).
Bowers et al. [35] demonstrated that HGF/c-Met activates the PI3K/
Akt pathway in U-373 human malignant glioma cells. PI3K activates a
number of cell signaling pathways that include Akt activation through
phosphorylation at Thr308 and Ser473 [36]. Activated PI3K/Akt path-
way provides potent survival signals in GBM [37]. Activated PI3K/Akt
elicits a downstream cascade that activates the transcription of several
promoting factors essentially to hGBM survival, growth, and motility
[38]. Although our results point to a relationship between EGFR and
c-Met signaling, the relevance of these findings would be ideal if we
could identify EGFR/c-Met synergism with a pertinent PI3K/Akt
pathway. Total and phosphorylated forms of both Akt and PI3K
levels were observed to be decreased in shEGFR, PHA-665752, and
hUCBSC treatments (Figure 7C). Combination treatments of EGFR
Figure 7. hUCBSC treatment reduces pEGFR/p-c-Met interactions in JKR-14 cells. (A) Colocalization analysis of pEGFR and p-c-Met.
After hUCBSC coculture, both control and hUCBSC cells were fixed, permeabilized, and incubated with pEGFR and p-c-Met antibodies.
Cells were further incubated with Alexa Fluor 594 (red) and Alexa Fluor 488 (green) at room temperature for 1 hour. Digital images were
obtained by confocal microscopy. (B) Effect of total and phosphorylated forms of EGFR, c-Met, Stat3, and β-catenin in control and
hUCBSC-treated JKR-14 cells. Cell lysates were prepared as described in Materials and Methods. (C) EGFR and MET function through
the PI3K/Akt axis. The expression pattern of total and phosphorylated forms of Akt and PI3K was examined using standard immunoblot
analysis of the whole-cell lysates of U251 and 5310 cells obtained under the following conditions: shEGFR transfections, c-Met inhibitor
PHA-665752 treatments, and hUCBSC cocultures. (D) Combination treatments of erlotinib and PHA-665752 on p-AKT and p-PI3K expres-
sion. GAPDH served as a loading control.
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and c-Met inhibitors, erlotinib and PHA-665752, reduced the ex-
pression of the phosphorylated forms of both Akt and PI3K when
compared to their individual treatments (Figure 7D). Our studies
demonstrate the additive potential therapeutic role of hUCBSC in
downregulating EGFR/c-Met pathway through the suppression of
PI3K/Akt axis in glioblastoma cell lines.
Discussion
Dysregulation of tyrosine-kinase receptors is one plausible mechanism
by which malignant cancer cells confer resistance to novel anticancer
therapies. In this study, we evaluated the possible interactions of two
known receptor kinases, EGFR and c-Met, in glioma cells. The most
common hallmark of GBM biology is aberrant EGF/EGFR signaling,
a potent driver of glioma proliferation [39,40]. Aberrant EGFR sig-
naling in glioblastoma increases secreted HGF/scatter factor binding
to Met tyrosine kinase receptors, displaying their increased association
in malignancy and invasion [26]. Apart from EGFR dysregulation in
human lung, gastric carcinomas, and rhabdomyosarcomas, the c-Met
pathway is also an absolute requirement for their progression [15,41].
Earlier Engelman et al. [18] in lung cancer demonstrated the possible
involvement of c-Met–related signal transduction in offering resis-
tance to EGFR-targeting agents. Even with combinatorial anti–
EGFR-targeting and anti–c-Met–targeting agents, acquired resistance
was observed during the cancer treatment illustrating the need to iden-
tify other molecular therapeutic agents in EGFR-related and c-Met–
related cellular events [24]. In light of these facts, we focused our
present work on developing strategies to block the c-Met pathway in
combination with known anti–EGFR-targeting agents like erlotinib,
gefitinib, shEGFR, or c-Met inhibitor PHA-665752 and consider
future perspectives of this rationale in cancer therapeutics. In this study,
we have evaluated the relevance of EGFR-mediated and c-Met–
mediated signaling in glioma cell proliferation and survival. In addition,
we also analyzed whether EGFR and c-Met are functionally dependent
on each other for controlling such responses. Our results show that
both EGFR and c-Met demonstrate positive cross talk in glioma cells
to promote their proliferation, invasion, and migration. Our results also
indicate that EGFR-mediated downstream signaling represents an
integrated signaling cascade resulting from the coactivation of c-Met
receptors in glioblastoma.
For testing EGFR-targeted anticancer therapy, the selective EGFR-
TKIs gefitinib and erlotinib were administered to a cohort of patients
with lung cancer with a proven survival rate. These TKI drugs exert
their mode of action by competing with ATP for binding to the recep-
tor kinase pocket of the receptor, thereby blocking the respective recep-
tor activation. In patients with hGBM, clinical trials conducted using
these small-molecule EGFR kinase inhibitors demonstrated significant
recurrent tumor regression by about 15% to 20% [42]. Although the
EGFR gene is the most commonly amplified in patients with glioblas-
toma, only a small subgroup seems to benefit from the EGFR kinase
inhibitors, not correlating with tolerance to EGFR kinase inhibitors
[43]. This again illustrates a complex interplay of cell surface signaling
and downstream signaling pathways. In our studies using EGFR kinase
inhibitors, we observed that c-Met in particular was found to be inhib-
ited along with its phosphorylated form. Other key signaling molecules
like Stat3 and β-catenin were also observed to be reduced in their
expression levels. Similarly, using c-Met inhibitor, we observed reduced
activation of EGFR. These results suggest possible cross talk between
EGFR and c-Met and its essential role in various biologic activities of
glioma cells.
Despite rapid advances in EGFR oncological therapeutics over the
past decade, substantial room for progress still remains. Most patients
with cancer do not respond to EGFR inhibitor therapy, which im-
plies intrinsic resistance. It is observed that even in patients who
demonstrate clear tumor response to EGFR inhibitors will eventually
show disease progression, implying acquired resistance [44]. It is well
known that oncogenic tyrosine kinases initiate multiple signaling
pathways that can constitutively activate a large downstream network
upon their phosphorylation. Recently, it is observed that the c-Met is
activated in the setting of EGFR resistance or blockade. Various re-
searchers have suggested that although c-Met and EGFR may not
interact directly, c-Met activation provides greater resistance to
EGFR inhibitors. Moreover, silencing of EGFR is compensated by
c-Met signaling. We focused our work to address the hypothesis that
activation of c-Met contributes to glioblastomal tumorigenesis and to
resistance to EGFR inhibition where c-Met targeting strategies might
have therapeutic benefit alone or in combination with EGFR inhibi-
tors. In uveal melanoma, it is reported that EGFR and c-Met knock-
down reduces proliferative effect, whereas elevated EGFR and c-Met
enhances to their greatest migration potential. It is also reported that
the pathogenesis of uveal melanoma is categorized by levels of c-Met
and EGFR expression, which are associated with migratory/invasiveness
responses to soluble factors present at high levels in the liver providing
biologic relevance for its clinical behavior with potential therapeutic
implications [45]. In another report, Martinez-Palacian et al. [46]
investigated the significance of the EGFR signaling and potential func-
tional cross talk between the c-Met and the EGFR pathways in oval
cell proliferation and survival and found that EGFR induced prolifer-
ation and survival equally in Met (flx/flx) and Met (−/−), suggesting
that EGFR signaling does not rely on c-Met activity and EGFR func-
tions independent of c-Met. In contrast, Liu et al. demonstrated that
activated c-Met positively regulates the EGFR activity and this acti-
vation is reversed upon the inhibition of c-Met in SNU-5, SNU-1,
U-87MG, 786-O, A549, H441, H596, H1437, H1993, BT474,
A549, and HT-29 cell lines, suggesting the pleotrophic effects of c-Met
on multiple signaling pathways. Recently, in non–small cell lung cancer,
it is observed that c-Met activation is associated with EGFR resistance
to inhibition, suggesting a possible interaction [47]. In the squamous
cell carcinoma, it is reported that combining inhibitors for EGFR and
c-Met lead to the greatest decrease in cell proliferation and invasion,
compared to the single inhibitor treatments [48]. In another study,
delayed c-Met activation in non–small lung cell lung carcinoma was
initiated by wild-type EGFR. EGFR phosphorylates c-Met and this
occurs without the supplementation of growth factors, suggesting
the nonligand activation and interdependence of EGFR and c-Met
pathways [49].
As an alternative to direct TKI inhibition, we tested if the hUCBSC
coculture treatment decreases the constitutive activation of EGFR/
c-Met pathway and the resultant effect on the downstream signaling
pathway. Coculture treatments of hUCBSC with glioma cells dem-
onstrated reduced expression levels of total and phosphorylated
forms of EGFR and pEGFR. In addition, the attenuation in EGFR,
c-Met, Stat3, and β-catenin levels was also observed to be reduced
by more than 50%. These results were confirmed using shEGFR-
treated cells, which were cocultured with hUCBSC. The expression
levels of the aforementioned proteins were reduced and are compa-
rable to the TKI treatments. We also proved that hUCBSC were
efficient against exogenously supplied EGF treatments of glioma
cells [50].
390 hUCBSC Regulates EGFR/c-Met Expression in hGBM Velpula et al. Translational Oncology Vol. 5, No. 5, 2012
RTK coactivation is an alternative mechanism by which GBM
mediates chemoresistance to EGFR inhibitor monotherapy [22].
Although in vitro studies suggest that inhibition of individual RTKs
is insufficient to eliminate downstream oncogenic pathways, chemical
inhibition or genetic depletion of multiple RTKs (such as c-Met and
PDGF receptor) in combination with EGFRvIII inhibition led to
enhanced GBM cell death [22,23,51]. These studies have provided
insight into the contribution of RTK coactivation to GBM chemo-
resistance, but the mechanisms underlying this process and the clin-
ical relevance of integrated signaling networks that result from the
activation of multiple RTKs remain poorly understood [22]. In our
studies with hUCBSC alone or in combination with other inhibitors,
we have shown that hUCBSCs are capable of inhibiting the coactiva-
tion of RTKs in glioma cells, thereby inhibiting their migratory and
invasive capacities. Targeting both EGFR and c-Met resulted in sig-
nificantly more inhibition of invasion, wound healing, and down-
stream signaling. Finally, targeting these two signaling pathways in
glioma cells isolated from an hGBM patient specimen and treating
them with hUCBSC demonstrated antitumor effects, providing pre-
clinical support that targeting EGFR/c-Met axis using hUCBSC
might be a promising therapeutic strategy for treating glioblastoma.
On the basis of our previous reports, we have continuously ob-
served that hUCBSC reduced the expression of several molecules
implicated in glioblastoma and that exposure of hUCBSC reduces
glioma cell migration and invasion. However, the actual mechanism
underlying this reduction in glioblastomal malignancy when treated
with hUCBSC needs to be studied. With the development of
hUCBSC-based targeted therapies, it will be possible to study the
oncogenic mechanisms of glioblastoma. Studies on cells isolated from
hGBM patient biopsies and their treatment with hUCBSC will allow
us to create patient-tailored combination therapies. It will be critical
to screen these treatments for toxicity and adverse effects, given their
potential to be therapeutic agents. A favorable strategy ostensibly
might be a combinatorial therapy. In the future, as we accumulate
more human biopsies and treat them with hUCBSC at laboratory
levels, the ability to completely shut off deregulated pathways in can-
cer cells will hopefully lead to less drug resistance and increased pa-
tient survival. Our present study concludes the high interdependency
between the expression of activation of both EGFR and c-Met recep-
tors contributing to glioblastoma malignancy. Knockdown or kinase
inhibition of EGFR suppresses c-Met expression and signaling, whereas
combination of EGFR and c-Met silencing leads to greater antitumor
effects. Finally, we conclude that coculture of GBM cells and xenografts
with hUCBSC inhibits EGFR and c-Met expression, signaling, and
association, and their combination treatment with EGFR and c-Met
inhibitors showed enhanced additive antitumor effect.
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Figure W1. Treatment of U251 and 5310 cells with TKIs. (A) U251
and 5310 cells were treated with 5 and 10 μM concentrations of
erlotinib and gefitinib for 9 hours. Total RNA was isolated as de-
scribed inMaterials andMethods. Reverse transcription–polymerase
chain reaction analysis was done to determine EGFR expression
in the TKI treatments. (B and C) FACS analysis demonstrating the
increased cell death in both erlotinib and gefitinib treatments at high
concentrations (10 μM).
Figure W2. (A) Invading cells were scored by counting four fields per membrane. Control was set to 100, and the percent invaded cells
were represented in graphical format. (B) GBM tissue specimen lysates for Western blot analysis were prepared as described previously
[28]. In vivo expression was studied by loading equal amounts of protein (40 μg) from tissue lysates onto 8% to 12% SDS-PAGE gels and
probing with desired antibodies.
